Conduit Pharmaceuticals Inc. (CDT)vsBeiGene, Ltd. (ONC)
CDT
Conduit Pharmaceuticals Inc.
$0.49
+1.60%
HEALTHCARE · Cap: $1.78M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
CDT
Avoid27
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CDT.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CDT
The strongest argument for CDT centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : CDT
The primary concerns for CDT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
CDT profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
CDT carries more volatility with a beta of 1.81 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
CDT generates stronger free cash flow (181M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 27/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Conduit Pharmaceuticals Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Conduit Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in oncology and rare diseases. Utilizing its proprietary drug delivery platform, Conduit aims to significantly enhance the efficacy and safety of existing therapies while minimizing side effects to improve patient outcomes. Backed by a seasoned management team with extensive experience in biopharmaceutical development, the company is well-positioned to generate strategic partnerships that can accelerate the growth of its promising product pipeline. With a commitment to pioneering therapeutic solutions, Conduit Pharmaceuticals is poised to become a vital contributor to advancements in healthcare.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?